SEC Tracker
Get the app

Q32 Bio QTTB

Q32 Bio announces Q3 2026 financial results and clinical updates.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Cash and cash equivalents of $289.6 million as of September 30, 2026.
  2. SIGNAL-AA Part B showed a 35.3% mean SALT score reduction at Week 36.
  3. 40.0% of patients achieved SALT-20 response at Week 36 in mITT analysis.
  4. Registration-directed program for bempikibart in severe AA expected to start in 1H'2027.

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Q32 Bio files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

  1. The press release highlights additional 36-week results and 16-week off-drug findings from Part B of the SIGNAL-AA clinical trial of bempikibart.
  2. These data support further development of the drug as a chronic treatment for alopecia areata.
  3. The SIGNAL-AA Part B open-label extension is ongoing, with data expected in 2H'2027.
  4. Q32 Bio also announced the initiation of a registration-directed program for bempikibart in patients with severe or very severe AA, expected to begin in 1H'2027.
  5. The company strengthened its leadership team with new appointments.
  6. Cash and cash equivalents were $289.6 million as of September 30, 2026.

6 of 6 claims matched the filing text.

For perspective, checked against its own source

From the 10-Q for the quarter ended June 30, 2026

  • For the quarter ended June 30, 2026, Q32 Bio reported a net loss of $8.9 million.

From the filing

Item 2.02 Results of Operations and Financial Condition.

Item 2.02 Results of Operations and Financial Condition.

On November 4, 2026, Q32 Bio Inc. announced its financial results for the quarter ended September 30, 2026 and provided a corporate update. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

Item 9.01 Financial Statements and Exhibits.

99.1

Press Release issued by Q32 Bio Inc. on November 4, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Q32 BIO INC.

Date:

November 4, 2026

By:

/s/ Jodie Morrison

Name:

Title:

Jodie Morrison

Chief Executive Officer

Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update

-- Presented additional 36-week results and 16-week off-drug findings from Part B of the SIGNAL-AA clinical trial of bempikibart in late-breaking oral and poster presentations at EADV Congress 2026;1 data supports further development of bempikibart as a chronic treatment in AA --2

-- Robust durability, including maintenance and deepening of response, observed through the 16-week off-drug period in Part B supporting potential for less frequent, chronic maintenance dosing --

-- SIGNAL-AA Part B open-label extension (OLE) ongoing; data expected in 2H'2027 --3

-- Registration-directed program evaluating bempikibart in patients with severe or very severe AA expected to initiate in 1H'2027 subject to planned regulatory discussions this quarter --4

-- Strengthened leadership team including appointments of Jos Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer --5

-- Cash and cash equivalents of $289.6 million as of September 30, 2026 expected to provide financial runway through Phase 3 topline results from planned registration-directed program --6 WALTHAM, Mass.— November 4, 2026 – Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and inflammatory diseases, today reported financial results for the quarte

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Kiora Pharmaceuticals KPRX public float $10M, Jun 30, 2025
  2. Brainstorm Cell Therapeutics BCLI public float $10M, Jun 30, 2025
  3. Scienture Holdings SCNX public float $10M, Jun 30, 2025
  4. LeonaBio ATHA public float $10M, Jun 30, 2025
  5. Mannatech MTEX public float $10M, Jun 30, 2025